Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studies

Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studies

Blog Article

ABSTRACTVaccines utilizing modified messenger RNA (mRNA) technology have shown robust protective efficacy against SARS-CoV-2 in humans.As the virus continues to evolve in both human and non-human hosts, risk Knitting Patterns remains that the performance of the vaccines can be compromised by new variants with strong immune escape abilities.Here we present preclinical characterizations of a novel bivalent mRNA vaccine RQ3025 for its safety and effectiveness in animal models.The mRNA sequence of the vaccine is designed to incorporate common mutations on the SARS-CoV-2 spike protein that have been discovered along the evolutionary paths of different variants.Broad-spectrum, high-titer neutralizing antibodies against multiple variants were induced in mice (BALB/c and K18-hACE2), 36" Gas Cooktop hamsters and rats upon injections of RQ3025, demonstrating advantages over the monovalent mRNA vaccines.

Effectiveness in protection against several newly emerged variants is also evident in RQ3025-vaccinated rats.Analysis of splenocytes derived cytokines in BALB/c mice suggested that a Th1-biased cellular immune response was induced by RQ3025.Histological analysis of multiple organs in rats following injection of a high dose of RQ3025 showed no evidence of pathological changes.This study proves the safety and effectiveness of RQ3025 as a broad-spectrum vaccine against SARS-CoV-2 variants in animal models and lays the foundation for its potential clinical application in the future.